Last reviewed · How we verify

Ironwood Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Ironwood Pharmaceuticals, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
XOI XOI marketed Guanylate cyclase-C agonist GC-C (guanylate cyclase-C) Gastroenterology
Microgestin® Microgestin® marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor, progesterone receptor Contraception / Women's Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 1 shared drug class
  2. EA Pharma Co., Ltd. · 1 shared drug class
  3. Helsinki University Central Hospital · 1 shared drug class
  4. Md Mehedi Shahriar · 1 shared drug class
  5. Oregon Health and Science University · 1 shared drug class
  6. Organon and Co · 1 shared drug class
  7. Teva Pharmaceuticals USA · 1 shared drug class
  8. University of Colorado, Denver · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ironwood Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Ironwood Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ironwood-pharmaceuticals-inc. Accessed 2026-05-16.

Related